Search Results - "Aul, C"

n-Butane: Ignition delay measurements at high pressure and detailed chemical kinetic simulations by Healy, D., Donato, N.S., Aul, C.J., Petersen, E.L., Zinner, C.M., Bourque, G., Curran, H.J.

“…Ignition delay time measurements were recorded at equivalence ratios of 0.3, 0.5, 1, and 2 for n-butane at pressures of approximately 1, 10, 20, 30 and 45 atm…”
Get full text

Oxidation of C1−C5 Alkane Quinternary Natural Gas Mixtures at High Pressures by Healy, D, Kalitan, D. M, Aul, C. J, Petersen, E. L, Bourque, G, Curran, H. J

“…Rapid compression machine (RCM) and shock-tube facilities have been employed to study the oxidation of natural gas blends at high pressure and intermediate to…”
Get full text

Isobutane ignition delay time measurements at high pressure and detailed chemical kinetic simulations by Healy, D., Donato, N.S., Aul, C.J., Petersen, E.L., Zinner, C.M., Bourque, G., Curran, H.J.

“…Rapid compression machine and shock-tube ignition experiments were performed for real fuel/air isobutane mixtures at equivalence ratios of 0.3, 0.5, 1, and 2…”
Get full text

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification by Nachtkamp, K., Strupp, C., Vukelja, M., Kasprzak, A., Haase, D., Ganster, C., Hildebrandt, B., Betz, B., Giagounidis, A., Aul, C., Blum, S., Hofmann, W. K., Pfeilstöcker, M., Valent, P., Lübbert, M., Seidl, M., Rudelius, M., Stauder, R., Krieger, O., Götze, K. S., Bobak, J., Kündgen, A., Schulz, F., Dietrich, S., Kobbe, G., Gattermann, N., Germing, U.

Get full text

Who Classification 2016 for the Myelodysplastic Syndromes (MDS): Main Changes by Strupp, C, Aul, C, Germing, U

Get full text

High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG by Lengfelder, E, Haferlach, C, Saussele, S, Haferlach, T, Schultheis, B, Schnittger, S, Ludwig, W-D, Staib, P, Aul, C, Grüneisen, A, Kern, W, Reichle, A, Serve, H, Berdel, W E, Braess, J, Spiekermann, K, Wörmann, B, Sauerland, M-C, Heinecke, A, Hiddemann, W, Hehlmann, R, Büchner, T

“…The objective of this study for newly diagnosed acute promyelocytic Leukemia (APL) was to evaluate the efficacy of an intensified double induction chemotherapy…”
Get full text

Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML by Schuler, E., Frank, F., Hildebrandt, B., Betz, B., Strupp, C., Rudelius, M., Aul, C., Schroeder, T., Gattermann, N., Haas, R., Germing, U.

“…•MDS patients with monocytic marrow proliferation have a more CMML-like phenotyp.•MDS patients with monocytic marrow proliferation have a more CMML-like…”
Get full text

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment by Gratwohl, A, Pfirrmann, M, Zander, A, Kröger, N, Beelen, D, Novotny, J, Nerl, C, Scheid, C, Spiekermann, K, Mayer, J, Sayer, H G, Falge, C, Bunjes, D, Döhner, H, Ganser, A, Schmidt-Wolf, I, Schwerdtfeger, R, Baurmann, H, Kuse, R, Schmitz, N, Wehmeier, A, Th Fischer, J, Ho, A D, Wilhelm, M, Goebeler, M-E, Lindemann, H W, Bormann, M, Hertenstein, B, Schlimok, G, Baerlocher, G M, Aul, C, Pfreundschuh, M, Fabian, M, Staib, P, Edinger, M, Schatz, M, Fauser, A, Arnold, R, Kindler, T, Wulf, G, Rosselet, A, Hellmann, A, Schäfer, E, Prümmer, O, Schenk, M, Hasford, J, Heimpel, H, Hossfeld, D K, Kolb, H-J, Büsche, G, Haferlach, C, Schnittger, S, Müller, M C, Reiter, A, Berger, U, Saußele, S, Hochhaus, A, Hehlmann, R

“…Tyrosine kinase inhibitors represent today’s treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT)…”
Get full text

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study by Germing, U, Lauseker, M, Hildebrandt, B, Symeonidis, A, Cermak, J, Fenaux, P, Kelaidi, C, Pfeilstöcker, M, Nösslinger, T, Sekeres, M, Maciejewski, J, Haase, D, Schanz, J, Seymour, J, Kenealy, M, Weide, R, Lübbert, M, Platzbecker, U, Valent, P, Götze, K, Stauder, R, Blum, S, Kreuzer, K-A, Schlenk, R, Ganser, A, Hofmann, W-K, Aul, C, Krieger, O, Kündgen, A, Haas, R, Hasford, J, Giagounidis, A

“…Myelodysplastic syndromes (MDS) with del(5q) are considered to have a benign course of the disease. In order to address the issue of the propensity of those…”
Get full text

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia by Krug, U, Berdel, W E, Gale, R P, Haferlach, C, Schnittger, S, Müller-Tidow, C, Braess, J, Spiekermann, K, Staib, P, Beelen, D, Serve, H, Schliemann, C, Stelljes, M, Balleisen, L, Maschmeyer, G, Grüneisen, A, Eimermacher, H, Giagounidis, A, Rasche, H, Hehlmann, R, Lengfelder, E, Thiel, E, Reichle, A, Aul, C, Ludwig, W-D, Kern, W, Haferlach, T, Köpcke, W, Görlich, D, Sauerland, M C, Heinecke, A, Wörmann, B J, Hiddemann, W, Büchner, T

“…We randomized 3375 adults with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome to test whether increasingly intensive…”
Get full text

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q by Mallo, M, Cervera, J, Schanz, J, Such, E, García-Manero, G, Luño, E, Steidl, C, Espinet, B, Vallespí, T, Germing, U, Blum, S, Ohyashiki, K, Grau, J, Pfeilstöcker, M, Hernández, J M, Noesslinger, T, Giagounidis, A, Aul, C, Calasanz, M J, Martín, M L, Valent, P, Collado, R, Haferlach, C, Fonatsch, C, Lübbert, M, Stauder, R, Hildebrandt, B, Krieger, O, Pedro, C, Arenillas, L, Sanz, M Á, Valencia, A, Florensa, L, Sanz, G F, Haase, D, Solé, F

“…This cooperative study assessed prognostic factors for overall survival (OS) and risk of transformation to acute myeloid leukemia (AML) in 541 patients with de…”
Get full text

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 by GIAGOUNIDIS, A. A. N, GERMING, U, AUL, C, HAASE, S, HILDEBRANDT, B, SCHLEGELBERGER, B, SCHOCH, C, WILKENS, L, HEINSCH, M, WILLEMS, H, AIVADO, M

“…We analyzed data of 76 consecutive patients with myelodysplastic syndrome (MDS) and isolated del(5q) (n=66) or del(5q) plus one additional chromosomal…”
Get full text

Validation of a New Clinically Based Classification System for Stratification of Prognosis in Patients with CMML by Rautenberg, C, Schuler, E, Nachtkamp, K, Schroeder, T, Blum, S, Aul, C, Haas, R, Germing, U

Get full text

Myelodysplastic Syndromes Showing Slight Monocytic Marrow Proliferation Are Prone to Progress to CMML by Schuler, E, Frank, F, Betz, B, Hildebrandt, B, Aul, C, Strupp, C, Schroeder, T, Haas, R, Germing, U

Get full text

Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients by Schroeder, T., Ruf, L., Bernhardt, A., Hildebrandt, B., Aivado, M., Aul, C., Gattermann, N., Haas, R., Germing, U.

“…Patients not fulfilling minimal criteria for myelodysplastic syndromes (MDS) but presenting with persisting cytopenia(s) not attributable to a haematological…”
Get full text

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) by GERMING, U, HILDEBRANDT, B, STAUDE, R, GIAGOUNIDIS, A. A. N, STRUPP, C, KÜNDGEN, A, MUELLER, T, HAAS, R, GATTERMANN, N, AUL, C, PFEILSTÖCKER, M, NÖSSLINGER, T, VALENT, P, FONATSCH, C, LÜBBERT, M, HAASE, D, STEIDL, C, KRIEGER, O

“…The international prognostic scoring system (IPSS) is considered the gold standard for risk assessment in primary myelodysplastic syndromes (MDS). This score…”
Get full text

Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide by Giagounidis, A A N, Kulasekararaj, A, Germing, U, Radkowski, R, Haase, S, Petersen, P, Göhring, G, Büsche, G, Aul, C, Mufti, G J, Platzbecker, U

Get full text

International Scoring System for evaluating prognosis in myelodysplastic syndromes by GREENBERG, P, COX, C, OHYASHIKI, K, TOYAMA, K, AUL, C, MUFTI, G, BENNETT, J, LEBEAU, M. M, FENAUX, P, MOREL, P, SANZ, G, SANZ, M, VALLESPI, T, HAMBLIN, T, OSCIER, D

“…Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome for patients with myelodysplastic syndrome (MDS), imprecision…”
Get full text

Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup by Giagounidis, A A N, Germing, U, Strupp, C, Hildebrandt, B, Heinsch, M, Aul, C

“…The survival of patients with myelodysplastic syndromes is strongly affected by chromosomal abnormalities. Patients with an isolated del(5q31) have a…”
Get full text

Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification by MATSUDA, A, GERMING, U, BESSHO, M, GATTERMANN, N, AUL, C, TOMONAGA, M, JINNAI, I, IWANAGA, M, MISUMI, M, KUENDGEN, A, STRUPP, C, MIYAZAKI, Y, TSUSHIMA, H, SAKAI, M

“…In the criteria of refractory cytopenia with multilineage dysplasia (RCMD) according to the WHO (World Health Organization) classification, the frequency…”
Get full text